A Phase I Study of Sapanisertib and Telaglenastat in Patients with Advanced Non-Small Cell Lung Cancer

Share
Print

Full Title

A Phase 1 Trial of MLN0128 (sapanisertib) and CB-839 HCl (telaglenastat) in Advanced NSCLC Patients (NCI 10327) (CIRB)

Purpose

This study is assessing the side effects and determining the best dose of telaglenastat that can be given together with sapanisertib to treat patients with non-small cell lung cancer (NSCLC) that has spread to other places in the body. Telaglenastat and sapanisertib may stop the growth of tumor cells by blocking some of the factors that cancer cells need to grow. Both drugs are taken orally (by mouth).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have recurrent or metastatic NSCLC that continues to grow despite treatment with platinum-based chemotherapy and/or immunotherapy. Patients with NSCLC containing EGFR, ALK, ROS1, or BRAF V600E/K mutations must have cancer that continued to grow despite targeted therapies.
  • Patients should recover from the serious side effects of previous therapies before receiving the study treatment.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients ages 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Paul Paik at 646-608-3759.

Protocol

20-399

Phase

I

Investigator

Co-Investigators